Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACORNASDAQ:BCLINASDAQ:CSBRNASDAQ:GMDANASDAQ:SURF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCLIBrainstorm Cell Therapeutics$1.14-2.6%$1.17$0.72▼$6.45$11.51M0.22388,376 shs98,008 shsCSBRChampions Oncology$7.77-19.6%$10.15$3.60▼$11.99$107.43M0.4442,826 shs32,633 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsSURFSurface Oncology$1.07$1.01$0.56▼$1.43$65.08M1.75430,375 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics+5.41%-0.85%+5.41%-4.88%-77.90%CSBRChampions Oncology+7.34%+5.24%+34.62%-5.72%+61.21%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%SURFSurface Oncology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics4.1201 of 5 stars3.54.00.04.70.60.80.6CSBRChampions Oncology4.3457 of 5 stars3.53.00.04.40.62.51.3GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ASURFSurface OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/ABCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,531.58% UpsideCSBRChampions Oncology 3.00Buy$12.0054.44% UpsideGMDAGamida Cell 0.00N/AN/AN/ASURFSurface Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACSBRChampions Oncology$50.15M2.14N/AN/A($0.14) per share-55.50GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00SURFSurface Oncology$30M2.17N/AN/A$0.81 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/ABCLIBrainstorm Cell Therapeutics-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)CSBRChampions Oncology-$7.28M-$0.0617.66∞N/A10.97%656.65%24.04%N/AGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/ASURFSurface Oncology-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/ALatest CSBR, BCLI, ACOR, GMDA, and SURF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ASURFSurface OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCLIBrainstorm Cell TherapeuticsN/A0.210.21CSBRChampions OncologyN/A0.990.99GMDAGamida Cell213.142.162.09SURFSurface OncologyN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCLIBrainstorm Cell Therapeutics14.33%CSBRChampions Oncology41.30%GMDAGamida Cell50.34%SURFSurface Oncology37.21%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCLIBrainstorm Cell Therapeutics11.15%CSBRChampions Oncology46.98%GMDAGamida Cell3.40%SURFSurface Oncology12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCLIBrainstorm Cell Therapeutics409.84 million8.74 millionOptionableCSBRChampions Oncology14313.83 million7.33 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableSURFSurface Oncology3560.82 million53.53 millionNot OptionableCSBR, BCLI, ACOR, GMDA, and SURF HeadlinesRecent News About These CompaniesHepatocellular Carcinoma Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 7, 2025 | theglobeandmail.comNovel Leukemia Target Found in RNA-Binding Cell Surface ProteinApril 23, 2025 | genengnews.comGInternational conference at the Thangam Cancer Center - Experts delivering edging Tech in Medical field at NamakkalJanuary 25, 2025 | msn.comThree-days conference at Thangam Cancer Center; providing insights on the international norms to treat advanced cancersJanuary 8, 2025 | news.webindia123.comNResearch Spotlight: Improving liver cancer outcomes through enhanced immunotherapyDecember 14, 2024 | eurekalert.orgECan estrogen cream combat skin aging signs? Here’s what dermatologists say.November 14, 2024 | washingtonpost.com‘Tremendous potential’: Cell therapy shows promise in treating deadly brain cancer in new trialNovember 14, 2024 | msn.comCAR-T therapy offers hope against an incurable brain tumor: patient shows no sign of disease after four yearsNovember 14, 2024 | msn.comTreatment offers promise for 'terrible, terrible' brain cancer in young peopleNovember 14, 2024 | msn.comQ3 2024 Heron Therapeutics Inc Earnings CallNovember 13, 2024 | finance.yahoo.comHow wearable tech can help women fight breast cancerNovember 13, 2024 | livemint.comAura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12, 2024 | markets.businessinsider.comVANCE trial marks milestone in t cell therapy for solid tumorsNovember 12, 2024 | msn.comLargest T cell clinical trial in solid tumors explores potential for precision immunotherapyNovember 12, 2024 | medicalxpress.comMNammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myelomaNovember 11, 2024 | pharmabiz.comPLargest T cell clinical trial in solid tumors heralds new era in precision immunotherapyNovember 11, 2024 | eurekalert.orgECAR T-Cell Therapy for Kidney Cancer Builds on Efficacy RecordNovember 9, 2024 | medpagetoday.comMNeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comEpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific MeetingsNovember 5, 2024 | finance.yahoo.comAntibody-based treatment for the most aggressive type of breast cancer could also treat other cancersNovember 4, 2024 | medicalxpress.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSBR, BCLI, ACOR, GMDA, and SURF Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Brainstorm Cell Therapeutics NASDAQ:BCLI$1.14 -0.03 (-2.56%) Closing price 03:55 PM EasternExtended Trading$1.15 +0.01 (+1.23%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Champions Oncology NASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Surface Oncology NASDAQ:SURFSurface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.